Business Wire

CA-FORESCOUT

Share
Critical Infrastructure Still at High Risk: Forescout Research Spotlights 21 New Vulnerabilities

Forescout, a global cybersecurity leader, today released “SIERRA:21 – Living on the Edge,” an analysis of 21 newly discovered vulnerabilities within OT/IoT routers and open-source software components. The report — produced by Forescout Research – Vedere Labs, a leading global team dedicated to uncovering vulnerabilities in critical infrastructure — emphasizes the continued risk to critical infrastructure and sheds light on possible mitigations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231205915662/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Sierra:21 Infographic (Source: Forescout)

“SIERRA:21 – Living on the Edge” features research into Sierra Wireless AirLink cellular routers and some of its open-source components, such as TinyXML and OpenNDS. Sierra Wireless routers are popular — an open database of Wi-Fi networks shows 245,000 networks worldwide running Sierra Wireless for a variety of applications. For example, Sierra Wireless routers are used for police vehicles connecting to a central network management system or to stream surveillance video, in manufacturing plants for industrial asset monitoring, in healthcare facilities providing temporary connectivity and to manage electric vehicle charging stations. The 21 new vulnerabilities have the potential to stop vital communications that could impact everyday life.

Read the blog: Forescout Vedere Labs discloses 21 new vulnerabilities affecting OT/IoT routers

Forescout Research further finds:

  • The attack surface is expansive with 86,000 vulnerable routers still exposed online. Less than 10% of these routers are confirmed to be patched against known previous vulnerabilities found since 2019.
  • Regions with the highest number of exposed devices includes:
    • 68,605 devices in The United States
    • 5,580 devices in Canada
    • 3,853 devices in Australia
    • 2,329 devices in France
    • 1,001 devices in Thailand
  • Among the 21 vulnerabilities, one has critical severity (CVSS score 9.6), nine have high severity and 11 have medium severity. These vulnerabilities allow attackers to steal credentials, take control of a router by injecting malicious code, persist on the device and use it as an initial access point into critical networks.
  • Patching can’t fix everything. 90 percent of devices exposing a specific management interface have reached end of life, meaning they cannot be further patched.
  • It’s an uphill battle to secure supply chain components. Open-source software elements continue to go unchecked and increase the attack surface of critical devices, leading to vulnerabilities that may be hard for organizations to track and mitigate.

“We are raising the alarm today because there remain thousands of OT/IoT devices representing an increased attack surface that requires attention,” advises Elisa Constante, VP of Research, Forescout Research – Vedere Labs. “Vulnerabilities impacting critical infrastructure are like an open window for bad actors in every community. State-sponsored actors are developing custom malware to use routers for persistence and espionage. Cybercriminals are also leveraging routers and related infrastructure for residential proxies and to recruit into botnets. Our discoveries reaffirm the need for heightened awareness of the OT/IoT edge devices that are so often neglected.”

Sierra Wireless and OpenDNS have issued patches for the identified vulnerabilities. TinyXML is an abandoned open source project, so the upstream vulnerabilities will not be fixed and must be addressed downstream.

For more information, download the full report, “SIERRA:21 – Living on the Edge,” now at https://www.forescout.com/resources/sierra21-vulnerabilities.

Additional Resources:

About Forescout

Forescout Technologies, Inc., a global cybersecurity leader, continuously identifies, protects and helps ensure the compliance of all managed and unmanaged connected cyber assets – IT, IoT, IoMT and OT. For more than 20 years, Fortune 100 organizations and government agencies have trusted Forescout to provide vendor-agnostic, automated cybersecurity at scale. The Forescout® Platform delivers comprehensive capabilities for network security, risk and exposure management, and extended detection and response. With seamless context sharing and workflow orchestration via ecosystem partners, it enables customers to more effectively manage cyber risk and mitigate threats.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231205915662/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in

Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release

Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release

First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye